Cancer immunotherapy

#Cancer immunotherapy #Events #Immunotherapy #Oncology

This week in drug discovery (11-15 November) 

News round-up for 11-15 November by DDW Senior Digital Content Editor Diana Spencer. With the Society for Immunotherapy of Cancer (SITC) 2024 taking place in Houston recently, there have been a number of recent announcements regarding the clinical advancement of immunocytokines, METTL3 inhibitors, cancer vaccines, CAR-T therapies and immune… Read More

#News

Immunotherapy
#Cancer immunotherapy #eBook #Immunotherapy #Oncology

Where are the opportunities and advances in immunotherapy?

Immunotherapies are at the cutting edge of therapeutics research, offering some of the most advanced treatments for cancer and other diseases. These treatments leverage the body’s immune system to fight disease, spanning a range of different approaches, including immune checkpoint inhibitors, adoptive cell therapies, monoclonal antibodies, oncolytic virus therapy, cancer vaccines,… Read More

#News

Immunotherapy eBook
#Cancer immunotherapy #eBook #Immuno-oncology #Immunotherapy

Immunotherapy: Opportunities and advances

Immunotherapies are at the cutting edge of therapeutics research, offering some of the most advanced treatments for cancer and other diseases. This eBook, sponsored by Sino Biological, examines the latest innovations that are driving the market and overcoming the challenges associated with these treatments.

#DDW eBooks #Intelligence

Cancer immunotherapy
#Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #RNA #RNA modifying enzymes #Storm Therapeutics

Could RNA modifying enzymes boost response rates? 

Cancer immunotherapy has set new standards in cancer care, but many patients are still not responding. RNA modifying enzymes (RME) research could be a way to improve results. DDW’s Megan Thomas reflects on STORM Therapeutics’ approach for the future of this mechanism of action.   Turning points and catalysts March 2011… Read More

#Cancer Research #Exclusive Content #Opinion

T cells attack a cancer cell
#Assay development optimisation & technology #Cancer immunotherapy #Cancer research #Immuno-oncology #Immunotherapy #Oncology #Phase III trial

New podcast: The consistency and value of immunotherapy

This is the latest episode of the free DDW narrated podcast, titled “How technology is impacting drug discovery”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Immunotherapy offers survival extension for brain tumour patients and The evolution of assays for… Read More

#News

#BioNTech #Cancer immunotherapy #Cancer vaccine #European Commission #Immunology / Virology & Vaccines #mRNA #University College London Hospitals

First patient dosed in UK novel cancer vaccine trial

A lung cancer patient at University College London Hospitals (UCLH) is the first to receive a novel cancer vaccine designed to prime the immune system to recognise and fight cancer cells.  It is the first time this immunotherapy made by BioNTech will be studied in a clinical… Read More

#Cancer Research #News

Vaccine research
#Cancer immunotherapy #Immune response #Immunotherapy #Oncology #University of Turku

Discovery of protein’s role could improve cancer immunotherapies

Researchers at the University of Turku in Finland have discovered that the protein TIMP-1 plays a critical role in the immune system’s defence against cancer. TIMP-1 is produced by dendritic cells, which are responsible for initiating immune responses and boosting the immune system’s ability to recognise… Read More

#Cancer Research #News

#AACR #Cancer immunotherapy #Cancer research #Cancer therapeutics #Oncology

New DDW Highlights podcast: 15 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The cancer research news has been coming thick and fast from the American Association… Read More

#News

#AACR #Cancer immunotherapy #Cancer research #Cancer therapeutics #Oncology

This week in drug discovery (8-12 April) 

News round-up for 8-12 April by DDW Digital Content Editor Diana Spencer. The cancer research news has been coming thick and fast from the American Association of Cancer Research (AACR) Annual Meeting in San Diego this week, so our Friday round-up focuses on drug discovery in oncology. Read More

#News

European map
#Advanced Therapies Europe #Biologics / Biotechnology #Cancer immunotherapy #CAR-T #Cell and gene therapy #Cell therapy #Collaboration #Europe #Immuno-oncology #Market reporting #Oncology #Start-ups

New podcast: Why is Europe a drug discovery epicentre?

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: European drug discovery and development success stories,… Read More

#News

Business financing
#Cancer immunotherapy #Cancer vaccine #Financing #Immunotherapy #Nouscom #Oncology

Cancer immunotherapy company raises €67.5 million

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalised viral vector-based cancer vaccines, has raised €67.5 million in an oversubscribed Series C financing round. The proceeds will enable Nouscom to advance its pipeline and complete Phase II clinical trials with its cancer vaccine NOUS-209. Representatives from Andera Partners, Bpifrance… Read More

#Business & Investment #News

T cell attacking cancer cell
#Cancer immunotherapy #Cancer research #Events #Immunotherapy #Oncology

Latest advances in immunotherapy from SITC 2023

The Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (SITC 2023) took place on 1-5 November 2023, at San Diego Convention Center in San Diego, US. CAN-2409 in non-metastatic pancreatic cancer Candel Therapeutics reported on initial positive interim data from its Phase II clinical trial… Read More

#Cancer Research #News #Trending News

Cancer immunotherapy
#Cancer immunotherapy #Drug discovery #eBook #Immunotherapy #Oncology #Precision medicine

Where are the latest breakthroughs in immunotherapy?

The latest in the DDW eBook series ‘Immunotherapy: Where are the advances and breakthroughs?‘ is now available for download. This 24-page eBook sponsored by Sino Biological looks at the advances and breakthroughs taking place within immunotherapy. Download this exclusive eBook to learn more about: Advances in cancer… Read More

#News

Immunotherapy eBook
#Cancer immunotherapy #Drug discovery #eBook #Immunotherapy #Oncology #Precision medicine

Immunotherapy: Where are the advances and breakthroughs?

This 24-page eBook sponsored by Sino Biological looks at the advances and breakthroughs taking place within immunotherapy. Download this exclusive eBook to learn more about: Advances in cancer care: Where are the advances in treatments for triple-negative breast cancer? Drug development: Five years of oncology developments Why immunotherapy is here… Read More

#DDW eBooks #Intelligence

#Animal models #Cancer immunotherapy #Cell therapy #Covid-19 #Humanised Immune System (HIS) #Immunotherapy #Monoclonal antibodies #Mouse models #Oncology #Regulatory

Podcast: Immunotherapy, avelumab and the immunocompromised

This is the latest episode of the free DDW narrated podcast, “Immunotherapy, avelumab and protecting the immunocompromised”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Mice with humanised immune systems advance cell-based immunotherapy”, “… Read More

#News

Cancer immuno-oncology
#AI / data analytics / healthtech / informatics #Bispecific Antibodies #Bispecific therapeutics #Cambridge Healthtech Institute #Cancer immunotherapy #Events #Immuno-oncology #Next generation sequencing

Immuno-Oncology Summit Europe 2023: Programme highlights 

From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London. DDW’s Megan Thomas shares highlights from the event programmes.   Programmes   This year’s summit was made up of conference programmes, which included: Modulating the Tumour Microenvironment; Next-Generation Cell-Based Immunotherapies; Bispecific and Multi-Specific Antibody Therapeutics, and… Read More

#Cancer Research #Exclusive Content #Opinion